{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000075","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.656096+00:00","generated_at":"2026-05-16T13:40:02.314259+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease","bullets":["VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.","Dose-dependent pharmacological effect observed across 18 patients in three cohorts.","MAD portion with gluten challenge ongoing; data expected in second half of 2026.","VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000075","json":"https://secwatch.observer/filing/0001828185-25-000075.json","markdown":"https://secwatch.observer/filing/0001828185-25-000075.md","text":"https://secwatch.observer/filing/0001828185-25-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/0001828185-25-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/brns-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:40:02.314259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}